focus -WSS

focus

author：Wikipedia 2025-09-03 03:22:19 - browse：446

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Unmasking the 'centricity' illusion in clinical trials

WSS

Pharma’s losing bet in New Jersey

Stroke rates rising, especially in working

U.S. death rates show how politics are affecting public health

Bird flu makes raw milk dangerous to consume, mouse study finds

Guardant Health colon cancer test endorsed by FDA advisory panel

Protect nursing home residents from future pandemics

hotspot

focus

focus

In Memoriam: Notable people who died in 2023

Louisiana bill approved classifying abortion pills as controlled substances

Cancer drug shortages should be causing more outrage

The Bio Revolution is changing business and society

Jerome Adams on the need for new antivirals for Covid

Beyond aggravation: Constipation is an American epidemic

Virginia high school admissions case could be legal follow

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Bright Health sells Medicare Advantage business to Molina

Decentralized clinical trials need collaboration to achieve wider use

Wikipedia

Protect nursing home residents from future pandemics

Congress: Prevent baby formula shortages by passing a new bill

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Beyond aggravation: Constipation is an American epidemic

Protect nursing home residents from future pandemics

Beyond aggravation: Constipation is an American epidemic

explore

entertainment

explore

entertainment